Adolescent depression is a substantial public health problem which contributes to academic failure, poor social function, substance use disorders, teen pregnancy, chronic morbidity, and completed suicides. Existing treatment approaches for adolescent depression such as psychotherapy and antidepressant medications are often ineffective and do not target relevant neurobiology. Repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) is a Food and Drug Administration approved treatment of major depressive disorder in adults. In clinical practice 10 Hz (high frequency) rTMS is typically used to treat depression but prior studies suggest that 1 Hz (low frequency) rTMS may be as effective, more tolerable, and safer compared to 10 Hz rTMS. Initial studies of rTMS for adolescent depression are promising but the optimal dosing and brain effects of rTMS treatments may be different than adults. One theory is that treatment with rTMS impacts gamma-aminobutyric acid (GABA) and glutamate neurotransmitters. However, there are no biomarker approaches or clinical profiles to guide rTMS treatments in adolescents. To solve these problems we propose a novel dose finding and target validation study of rTMS for adolescent depression with a biomarker stratified randomized design. Depressed adolescents will be stratified according to a baseline measure of cortical glutamatergic tone called intracortical facilitation (ICF) and then randomized to six weeks of 1 Hz or 10 Hz rTMS treatment applied to the L-DLPFC. We will determine if baseline measures of ICF predict antidepressant response to 1 Hz or 10 Hz rTMS in depressed adolescents and if ICF measures change over time with successful rTMS treatment. The research team will study and develop biomarkers of GABA and glutamate tone with ultrahigh-field, 7 tesla (7 T) magnetic resonance spectroscopy (MRS) measures of the bilateral dorsolateral prefrontal cortices. We will also examine the effect of baseline anhedonia and historical adversity on treatment response to rTMS with the aim of understanding these clinical characteristics and developing clinical treatment targets with links to GABA and glutamate tone. We hypothesize that depressed adolescents with high baseline ICF measures will have a greater antidepressant response (assessed by greater decrease in Children?s Depression Rating Scale-Revised scores) to 1 Hz rTMS while depressed adolescents with low baseline ICF will have a greater antidepressant response to 10 Hz rTMS. We also hypothesize that 1 Hz rTMS will increase cortical GABA and decrease cortical glutamate, while 10 Hz rTMS will decrease cortical GABA and increase cortical glutamate (measured with bilateral 7 T MRS of the dorsolateral prefrontal cortices). The proposed research program will answer important questions regarding the neurobiology of adolescent depression, the mechanisms of rTMS treatments in adolescents, and dosing rTMS in adolescent depression. Findings will inform larger studies of rTMS and the development of novel treatments for adolescent depression.

Public Health Relevance

Adolescent depression has poorly understood biology and is a major public health problem. This project focuses on a therapeutic trial of a new treatment called repetitive transcranial magnetic stimulation (rTMS) for adolescent depression. The investigators will develop biomarkers of brain chemicals to guide treatment with rTMS and better understand adolescent depression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH113700-01
Application #
9372832
Study Section
Special Emphasis Panel (ZMH1)
Program Officer
Grabb, Margaret C
Project Start
2017-08-17
Project End
2022-06-30
Budget Start
2017-08-17
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Heath, Alesha; Lindberg, Daniel R; Makowiecki, Kalina et al. (2018) Medium- and high-intensity rTMS reduces psychomotor agitation with distinct neurobiologic mechanisms. Transl Psychiatry 8:126
Croarkin, Paul E (2018) Indexing the neurobiology of psychotic depression with resting state connectivity: Insights from the STOP-PD study. EBioMedicine 37:32-33
Doruk Camsari, Deniz; Kirkovski, Melissa; Croarkin, Paul E (2018) Therapeutic Applications of Invasive Neuromodulation in Children and Adolescents. Psychiatr Clin North Am 41:479-483
Lewis, Charles P; Nakonezny, Paul A; Blacker, Caren J et al. (2018) Cortical inhibitory markers of lifetime suicidal behavior in depressed adolescents. Neuropsychopharmacology 43:1822-1831
Croarkin, Paul E; Nakonezny, Paul A; Deng, Zhi-De et al. (2018) High-frequency repetitive TMS for suicidal ideation in adolescents with depression. J Affect Disord 239:282-290